Equity (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Equity [Abstract] |
|
| Schedule of Share Capital Activity |
Share capital activity was as follows (in thousands of shares of NIS 5 par value per share):
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares |
|
|
|
2025 |
|
|
2024 |
|
Shares outstanding as of January 1 |
|
|
215,777 |
|
|
|
235,597 |
|
Repurchase of treasury shares |
|
|
(14,424 |
) |
|
|
(26,043 |
) |
Exercise of warrants during the period |
|
|
— |
|
|
|
3 |
|
Exercise of share options and vesting of RSUs during the period |
|
|
5,459 |
|
|
|
6,220 |
|
Shares outstanding as of December 31 |
|
|
206,812 |
|
|
|
215,777 |
|
|
| Schedule of Stock Option Activity and Related Information |
A summary of the Company’s stock option activity and related information is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
of options |
|
|
Weighted
average
exercise price |
|
|
Weighted
average
intrinsic value |
|
Outstanding on December 31, 2024 |
|
|
2,627,095 |
|
|
$ |
2.30 |
|
|
$ |
0.80 |
|
Granted |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Exercised |
|
|
(323,649 |
) |
|
|
0.82 |
|
|
|
0.89 |
|
Forfeited and expired |
|
|
(2,005,112 |
) |
|
|
2.35 |
|
|
|
0.32 |
|
Outstanding on December 31, 2025 |
|
|
298,334 |
|
|
|
3.57 |
|
|
|
0.02 |
|
Exercisable as of December 31, 2025 |
|
|
228,334 |
|
|
|
3.53 |
|
|
|
0.03 |
|
|
| Schedule of Fair Value of the Options Granted |
The table below summarizes the assumptions used in determining the fair value of the options granted in 2023:
|
|
|
|
|
Range of expected share price volatility |
|
103.2%-121.85% |
|
Range of estimated term (years) |
|
4.5-8 |
|
Range of weighted average of risk-free interest rate |
|
4.33%-4.5% |
|
Expected dividend yield |
|
|
— |
|
|
| Schedule of Companies RSU Activity |
A summary of the Company’s RSU activity is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
average |
|
|
|
Number of Units |
|
|
grant price |
|
Outstanding on December 31, 2024 |
|
|
10,893,388 |
|
|
$ |
2.75 |
|
Granted |
|
|
12,195,051 |
|
|
|
1.61 |
|
Vested |
|
|
(5,135,973 |
) |
|
|
1.68 |
|
Forfeited |
|
|
(11,730,432 |
) |
|
|
1.89 |
|
Outstanding on December 31, 2025 |
|
|
6,222,034 |
|
|
$ |
1.86 |
|
|
| Schedule of Companies Warrants Activity and Related Information |
A summary of the Company’s warrants activity and related information is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
average |
|
|
|
|
|
|
Weighted |
|
|
remaining |
|
|
|
|
|
|
average |
|
|
contractual |
|
|
|
|
|
|
exercise |
|
|
life (in |
|
|
|
Warrants |
|
|
price |
|
|
years) |
|
Outstanding on December 31, 2024 |
|
|
34,817,626 |
|
|
$ |
6.26 |
|
|
|
1.24 |
|
Granted |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Expired |
|
|
(5,575,523 |
) |
|
|
7.80 |
|
|
|
— |
|
Outstanding and exercisable as of December 31, 2025 |
|
|
29,242,103 |
|
|
$ |
5.96 |
|
|
|
1.60 |
|
|
| Schedule of Stock Based Compensation Expense Related to Stock Options RSU and Warrants |
Stock-based compensation expense related to stock options and RSUs is included in the consolidated statements of operations and comprehensive loss as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, |
|
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
Cost of revenue |
|
$ |
669 |
|
|
$ |
938 |
|
|
$ |
811 |
|
Research and development expenses |
|
|
1,708 |
|
|
|
6,079 |
|
|
|
10,297 |
|
Sales and marketing expenses |
|
|
896 |
|
|
|
1,649 |
|
|
|
4,891 |
|
General and administrative expenses |
|
|
1,647 |
|
|
|
7,055 |
|
|
|
6,111 |
|
Discontinued operations |
|
|
939 |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
5,859 |
|
|
$ |
15,721 |
|
|
$ |
22,110 |
|
|